利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

1333 records (took 0.047 seconds)

    MEANS AND METHODS FOR RECOGNIZING THE DEVELOPMENT OF CARDIOVASCULAR DISEASE IN AN INDIVIDUAL
    81.
    发明申请
    MEANS AND METHODS FOR RECOGNIZING THE DEVELOPMENT OF CARDIOVASCULAR DISEASE IN AN INDIVIDUAL 审中-公开
    识别个体发生心血管疾病的手段和方法

    公开(公告)号：US20120122720A1

    公开(公告)日：2012-05-17

    申请号：US13318804

    申请日：2010-05-05

    Applicant: Irun R. Cohen ,  Eytan Domany ,  Eli Sahar ,  Noam Shental

    Inventor： Irun R. Cohen ,  Eytan Domany ,  Eli Sahar ,  Noam Shental

    IPC: C40B30/04 ,  C40B40/12 ,  C40B40/04 ,  C40B40/10 ,  C40B40/08

    CPC classification number: G01N33/6893 ,  G01N33/564 ,  G01N2333/47 ,  G01N2500/04 ,  G01N2800/324

    Abstract: A method of recognizing the development of an Acute Myocardial Infarction (AMI) process in an individual, wherein the method comprises steps of: profiling specific antibody reactivities or biomarkers associated with AMI susceptibility, the profiling comprises steps of: attaching a set of defined antigens to a substrate; obtaining a biological fluid derived specimen from an individual, the specimen containing a specific antibody repertoire; and binding said antibodies of the biological fluid specimen to the attached antigens thereby forming bound antibody antigen complexes; and analyzing results obtained, wherein the presence of the complexes is indicative of AMI.

    Abstract translation: 识别个体中急性心肌梗死（AMI）过程的发展的方法，其中所述方法包括以下步骤：分析与AMI易感性相关的特异性抗体反应性或生物标志物，所述分析包括以下步骤：将一组限定的抗原连接到 底物; 从个体获得生物流体衍生标本，含有特异性抗体库的样本; 并将所述生物流体标本的所述抗体结合至附着的抗原，从而形成结合的抗体抗原复合物; 并分析获得的结果，其中复合物的存在表示AMI。

    Nucleic Acid Analysis Using Sequence Tokens
    82.
    发明申请
    Nucleic Acid Analysis Using Sequence Tokens 有权
    使用序列标记进行核酸分析

    公开(公告)号：US20120108467A1

    公开(公告)日：2012-05-03

    申请号：US13211113

    申请日：2011-08-16

    Applicant: Sydney Brenner

    Inventor： Sydney Brenner

    IPC: C40B40/08 ,  C40B60/12 ,  C07H21/00 ,  C40B70/00

    CPC classification number: C12Q1/6837 ,  C12Q1/6827 ,  C12Q2563/179 ,  C12Q2537/113 ,  C12Q2525/186

    Abstract: The present invention provides methods and compositions for tagging nucleic acid sequence fragments, e.g., a set of nucleic acid sequence fragments from a single genome, with one or more unique members of a collection of oligonucleotide tags, or sequence tokens, which, in turn, can be identified using a variety of readout platforms. As a general rule, a given sequence token is used once and only once in any tag sequence. In addition, the present invention also provides methods for using the sequence tokens to efficiently determine variations in nucleotide sequences in the associated nucleic acid sequence fragments.

    Abstract translation: 本发明提供了用于标记核酸序列片段的方法和组合物，例如，来自单个基因组的一组核酸序列片段，与寡核苷酸标签或序列标记的集合的一个或多个唯一成员， 可以使用各种读出平台来识别。 作为一般规则，给定的序列令牌在任何标签序列中使用一次且仅一次。 此外，本发明还提供了使用序列令牌有效地确定相关核酸序列片段中的核苷酸序列变异的方法。

    Dual polarity analysis of nucleic acids
    83.
    发明申请
    Dual polarity analysis of nucleic acids 有权
    核酸双极性分析

    公开(公告)号：US20120108443A9

    公开(公告)日：2012-05-03

    申请号：US11444151

    申请日：2006-05-31

    Applicant: Elazar Rabbani ,  James J. Donegan

    Inventor： Elazar Rabbani ,  James J. Donegan

    IPC: C40B30/06 ,  C40B40/08

    CPC classification number: C12Q1/6809 ,  C12Q1/6813 ,  C12Q1/6844 ,  C12Q2565/525 ,  C12Q2565/501 ,  C12Q2531/143

    Abstract: This invention provides methods for characterizing the amounts of nucleic acids, including plus/minus determinations, the use of different constructs, the use of a library and a reference library. Expression may also be compared in two or more samples using the methods of this invention. Also provided are heterophasic arrays comprising labeled positive copies of nucleic acids hybridized to the array and labeled negative copies of nucleic acids hybridized to the array, in which the labeled positive copies are separately quantifiable from the labeled negative copies.

    Abstract translation: 本发明提供用于表征核酸量的方法，包括加/减确定，使用不同构建体，使用文库和参考文库。 也可以使用本发明的方法在两个或多个样品中比较表达。 还提供了包括与阵列杂交的核酸的标记阳性拷贝和标记的与阵列杂交的核酸的阴性拷贝的异相阵列，其中标记的阳性拷贝可从标记的阴性拷贝分开定量。

    COMPOSITIONS AND METHODS FOR PREDICTING HCV SUSCEPTIBILITY TO ANTIVIRAL AGENTS
    84.
    发明申请
    COMPOSITIONS AND METHODS FOR PREDICTING HCV SUSCEPTIBILITY TO ANTIVIRAL AGENTS 审中-公开
    预防HCV对抗病毒药物的敏感性的组合物和方法

    公开(公告)号：US20120077738A1

    公开(公告)日：2012-03-29

    申请号：US13229271

    申请日：2011-09-09

    Applicant: Robert Striker ,  Israr Ansari

    Inventor： Robert Striker ,  Israr Ansari

    IPC: A61K38/13 ,  A61P31/14 ,  C40B40/08 ,  C12Q1/70 ,  C07H21/00

    CPC classification number: C12Q1/707 ,  C12Q2600/136

    Abstract: Methods for determining the susceptibility of a hepatitis C virus (HCV) in a patient to anti-viral agents, particularly cyclophilin inhibitors such as cyclosporine A, are disclosed. The methods include determining the amino acid sequence within a region of the HCV NS5A protein and comparing the viral amino acid sequence to that of a reference strain, wherein the existence of at least one variant/mutation in the viral genome is indicative that the virus is more or less susceptible to anti-viral agents. Also disclosed are isolated polynucleotide molecules, replicons, and kits that can be used to assay the susceptibility of hepatitis HCV in a patient to anti-viral agents.

    Abstract translation: 公开了确定患者中丙型肝炎病毒（HCV）对抗病毒剂，特别是亲环蛋白抑制剂如环孢霉素A的易感性的方法。 所述方法包括测定HCV NS5A蛋白区域内的氨基酸序列，并比较病毒氨基酸序列与参照菌株的氨基酸序列，其中病毒基因组中存在至少一个变体/突变表明病毒是 或多或少对抗病毒剂敏感。 还公开了分离的多核苷酸分子，复制子和试剂盒，其可用于测定患者中丙型肝炎病毒对抗病毒剂的易感性。

    Universal Antibody Libraries
    89.
    发明申请
    Universal Antibody Libraries 审中-公开
    通用抗体库

    公开(公告)号：US20110245108A1

    公开(公告)日：2011-10-06

    申请号：US11571710

    申请日：2005-07-06

    Applicant: Roberto Crea ,  Arvind Rajpal ,  Guido Cappuccilli ,  Randy Shen ,  Toshihiko Takeuchi

    Inventor： Roberto Crea ,  Arvind Rajpal ,  Guido Cappuccilli ,  Randy Shen ,  Toshihiko Takeuchi

    IPC: C40B40/02 ,  C40B40/08 ,  C40B50/06

    CPC classification number: C07K16/00 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622

    Abstract: Universal antibody libraries are described which are synthetic and derived from expressed human antibody sequences selected accordingly to certain criteria, for example, that the sequences are derived from naturally-occurring antibodies expressed in response to a certain antigen class (e.g., small molecule, polysaccharide, peptide, or protein) and having CDR regions engineered for optimal diversity. Methods for making and screening such libraries for isolating therapeutics suitable for treating disease are also disclosed.

    Abstract translation: 描述了通用抗体文库，其是合成的，并且衍生自相应于某些标准的表达的人抗体序列，例如，所述序列衍生自响应某一抗原类别（例如小分子，多糖， 肽或蛋白质）并且具有被设计用于最佳多样性的CDR区域。 还公开了用于制备和筛选用于分离适合治疗疾病的治疗剂的文库的方法。

    METHODS FOR IDENTIFYING ERBB2 ALTERATION IN TUMORS
    90.
    发明申请
    METHODS FOR IDENTIFYING ERBB2 ALTERATION IN TUMORS 审中-公开
    用于鉴定肿瘤中ERBB2变化的方法

    公开(公告)号：US20110244459A1

    公开(公告)日：2011-10-06

    申请号：US13139072

    申请日：2009-12-09

    Applicant: Francois Bertucci ,  Rebecca Tagett ,  Sabrina Carpentier

    Inventor： Francois Bertucci ,  Rebecca Tagett ,  Sabrina Carpentier

    IPC: C12Q1/68 ,  G01N33/53 ,  C40B40/08

    CPC classification number: G01N33/574 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N2333/71

    Abstract: Methods for identifying ERBB2 (also named HER2) alteration in tumors, in particular cancer, based on the analysis of the expression of at least three genes of the ERBB2 amplicon located within less than one megabase on either side of ERBB2, and eventually of the gene corresponding to the Affymetrix probeset 234046_at (SEQ ID NO: 31), as well as a poynucleotide library useful for the molecular characterization of a cancer including polynucleotide sequences for detecting the genes, and a kit including the library.

    Abstract translation: 基于对位于ERBB2任一侧的不到一兆碱基的ERBB2扩增子的至少三个基因的表达的分析，以及最终的基因的分析，鉴定ERBB2（也称为HER2）改变肿瘤，特别是癌症的方法 对应于Affymetrix探针组234046_at（SEQ ID NO：31），以及可用于癌症分子表征的多核苷酸文库，包括用于检测基因的多核苷酸序列，以及包含该文库的试剂盒。

Patent Agency Ranking